Is KRYS or KTTA more undervalued in 2026?

CirclFi compares Krystal Biotech, Inc. (KRYS) and Pasithea Therapeutics Corp. (KTTA) using 13 institutional-grade valuation models. KRYS has a Quality of Company score of 7.7/10 while KTTA scores 4.1/10.

Which is a better buy — KRYS or KTTA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KRYS and KTTA valuations compare?

KRYS at $310.30 and KTTA at $0.70 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KRYS vs KTTA Valuation Comparison 2026 — Intrinsic Value Analysis

KRYS

Biotechnology

Krystal Biotech, Inc.

Quality

7.7

out of 10

Value Trap

SAFE

Price

$310.30

Last close

Models

13/13

Active

KTTA

Biotechnology

Pasithea Therapeutics Corp.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$0.70

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	KRYS Fair Value	KRYS Upside	KTTA Fair Value	KTTA Upside
Bayesian DCF	Intrinsic	$137.31	-55.8%	$1.01	+45.1%
Earnings Power Value	Intrinsic	$61.44	-80.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$30.01	-90.3%	$1.72	+147.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KRYS vs KTTA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KRYS vs KTTA — Which Stock Is More Undervalued?

KRYS scores higher with a 7.7/10 quality rating vs KTTA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Krystal Biotech, Inc. (KRYS) and Pasithea Therapeutics Corp. (KTTA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KRYS currently trades at $310.30 with a QOC of 7.7/10, while KTTA trades at $0.70 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).